The number of cancer survivors in the United States is continuously growing. The growth is primarily attributed to the increased cancer screening efforts and significant improvement of cancer treatment. Within the last thirty years, the population of cancer survivors rose to 15.5 million and is expected to rise to 26.1 million by 2040. Half of the cancer survivors have lived for more than ten years after their first diagnosis and another two thirds have survived for more than five years.
The survivors have complicated health needs and need constant management of emerging diagnoses. Cancer survivors are usually excluded from cancer clinical trials. The restrictive eligibility criteria can exclude up to 25% of newly diagnosed patients suffering lung cancer. Significant scientific progress has been made to understand the risk of future primary cancer developing among cancer survivors, but it does not address how the patients diagnosed with cancer survived.
The report shows the prevalence of prior cancer cases among individuals who have been newly diagnosed from 2009 to 2013 by using the National Cancer Institute’s Surveillance. The prevalence of cancer was derived from SEER sequence numbers that represent the order of all primary reputable tumors. Sequence number 00 is an indication that one has only one primary cancer while 01 is a representation of the second and so on. With the growing number of cancer survivors, it is important to understand the nature and impact of a prior cancer which can be used in the generalization of results from the trials, patient experience, and disease outcomes.
Eric Lefkofsky was born on 2nd September 1969. He went to the University of Michigan and graduated with BA. He began his career journey by selling carpets at school, and after law school, he borrowed money alongside his friend Keywell to buy Wisconsin, an apparel company in Madison. The two created an internet company in 1999 which specialized in promotional products. The company experienced rapid internet growth and was later on sold to Hallo Industry in 2000.
Eric Lefkofsky is the chief executive officer and co-founder of Tempus. He is also the founding partner of Lightbank. Tempus has built an operating system which battles cancer while Lighbank is a venture fund which invests in disruptive technology.